Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (SHE:002932)

SHE:002932 Revenue

Wuhan Easy Diagnosis Biomedicine had revenue of 70.76M CNY in the quarter ending June 30, 2026, with 2.07% growth. This brings the company's total for the last twelve months to 267.22M, down -20.25% year-over-year. In the year 2025, Wuhan Easy Diagnosis Biomedicine had annual revenue of 265.08M, down -24.28%. That makes Wuhan Easy Diagnosis Biomedicine the 29,496th largest company in the world by revenue and 4,935th in China.

• Revenue (ttm): 267.22M
• Revenue Growth: -20.25%
• P/S Ratio: 11.40
• Revenue / Employee: 446.11K
• Employees: 599
• Market Cap: 3.05B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• In Vitro Diagnostic Products and Solutions 220.05M 83.0%
• Business Operations and Others 45.02M 17.0%

By Geography

Chart

• Central 67.81M 25.6%
• Northwestern 58.52M 22.1%
• Overseas 52.99M 20.0%
• Southwest 29.78M 11.2%
• Southern China 26.70M 10.1%
• Eastern China 17.64M 6.7%
• North China 9.49M 3.6%
• Northeast China 2.16M 0.8%

Fiscal year ended Dec 31, 2025 See the full SHE:002932 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	265.08M	-84.98M	-24.28%
Dec 31, 2024	350.06M	-399.47M	-53.30%
Dec 31, 2023	749.54M	-9.78B	-92.88%
Jan 1, 2023	10.53B	7.70B	272.12%
Jan 1, 2022	2.83B	1.87B	195.05%

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 18, 2026

Data Sources Report a data error